Jasper Therapeutics (JSPR) Projected to Release Earnings on Wednesday

Jasper Therapeutics (NASDAQ:JSPR) is expected to be posting its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Jasper Therapeutics to post earnings of ($0.38) per share for the quarter. Parties may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 4:00 PM ET.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Thursday, May 14th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.46) by $0.08. On average, analysts expect Jasper Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Jasper Therapeutics Stock Performance

Shares of JSPR stock opened at $0.67 on Wednesday. Jasper Therapeutics has a fifty-two week low of $0.32 and a fifty-two week high of $3.14. The stock has a 50 day simple moving average of $0.58 and a two-hundred day simple moving average of $0.95. The company has a market cap of $18.76 million, a P/E ratio of -0.21 and a beta of 3.02.

Institutional Investors Weigh In On Jasper Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its holdings in shares of Jasper Therapeutics by 11.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock worth $1,005,000 after purchasing an additional 23,453 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Jasper Therapeutics during the 1st quarter valued at $46,000. JPMorgan Chase & Co. increased its stake in Jasper Therapeutics by 1,074.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 65,088 shares of the company’s stock valued at $361,000 after purchasing an additional 59,547 shares in the last quarter. XTX Topco Ltd acquired a new position in Jasper Therapeutics during the second quarter worth $152,000. Finally, Marshall Wace LLP acquired a new position in Jasper Therapeutics during the second quarter worth $281,000. Institutional investors own 79.85% of the company’s stock.

Analysts Set New Price Targets

JSPR has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Royal Bank Of Canada set a $3.00 target price on shares of Jasper Therapeutics and gave the stock a “sector perform” rating in a research note on Friday, May 15th. TD Cowen cut shares of Jasper Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. Finally, Wall Street Zen upgraded shares of Jasper Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Four investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $12.00.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.